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a b s t r a c t
The C7N-aminocyclitol kirkamide was recently isolated from the plant obligate symbiont Candidatus
Burkholderia kirkii and was hypothesized to be beneficial to the plant host due to its cytotoxic activity
against insects and arthropods. To study its mechanism of action and inspired by its structural similarity
with N-acetylglucosamine (GlcNAc) and oseltamivir, kirkamide-oseltamivir hybrid derivatives were
synthesized and investigated for their biological activity. Interestingly, kirkamide analogues were
reasonably potent against a known bacterial neuraminidase.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Natural products remain a prime source of inspiration for the
development of new lead structures in drug discovery [1,2].
Recently, two novel natural products, kirkamide (1) and streptol
glucoside (2) have been isolated from an obligate symbiosis system
composed of the plant Psychotria kirkii and the bacterium Candi-
datus Burkholderia kirkii [3,4]. Synthetic routes towards accessing
these natural products and derivatives have been already identified
in the literature [3,5,6]. The discovery of kirkamide (1) was guided
by the genome-based prediction of 2-epi-5-epi-valiolone [7,8],
which is known to be involved in the biosynthesis of the C7N
aminocyclitol family, a rich source of bioactive compounds [9e13].
The cytotoxicity of kirkamide (1) was evaluated against several
organisms, such as insects and arthropods [3]. The structural sim-
ilarity between N-acetylglucosamine (3, GlcNAc), oseltamivir (4)
[14], and kirkamide (1) suggested that the natural aminocyclitol 1
could act as a glycoside hydrolase (glycosidase) inhibitor (Fig. 1).
The aim of this study was to (a) prepare hybrid compounds
between kirkamide (1) and oseltamivir (4), (b) investigate plausible
enzyme targets, and (c) evaluate the potential of oxidation at the
methylene allylic position of kirkamide (1) under biologically
relevant conditions. In order to reach these goals, we employed a
divergent synthetic route allowing for late stage modification of a
synthetic intermediate.
Fig. 1. Constitution and configuration of kirkamide (1), streptol glucoside (2), N-ace-
tylglucosamine (3, GlcNAc), and oseltamivir (4).
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2. Results and discussions
To achieve our aims, triflate 5 [3] was selected as the key in-
termediate for the synthesis of all compounds (Scheme 1). Evalu-
ation of different electrophilic precursors for the subsequent
carbonylation, both by us [3,6] and others [5], all provided evidence
for the superiority of enol triflates over enol halogenides. Conse-
quently, using the standard Pd-mediated carbonylation/esterifica-
tion conditions, the ethyl ester 6 was synthesized in good yield
(68%) and smoothly Si-deprotected using TBAF in THF to obtain the
alcohol 7. The benzyl deprotection was found to be challenging: In
contrast to the hydroxymethylene derivative in the kirkamide
synthesis [3], the ester 7 proved to be recalcitrant under classical
Birch conditions, eventually leading to the decomposition of the
startingmaterial. After screening of several Lewis acids, only BCl3 in
CH2Cl2 delivered the triol 8 in low yield. Pleasingly, the addition of
pentamethylbenzene [15] to this reaction mixture significantly
increased the yield; and the ester was subsequently saponifiedwith
KOH solution to obtain the kirkamide carboxylic acid derivative 8.
The free hydroxyl group of the available ester intermediate 7
(Scheme 2) was activated with mesyl chloride to obtain mesylate 9
(71%, purified by flash chromatography on silica) and its configu-
ration at position 1 was subsequently inverted, using KNO2, to the
C(1) epimer 10 [16]. Using the optimized deprotection conditions
developed earlier, the second kirkamide derivative 11 was
smoothly synthetized via debenzylation.
Taking advantage of the mesyl intermediate 9 (Scheme 3), the
amine 12 was synthesized in two steps composed of a SN2 type
reactionwith azide following by a Staudinger reaction using PPh3 as
reductant. We were pleased by the good yield of this two-step
procedure and the full deprotection was performed to obtain the
amine kirkamide derivative 13.
Synthetic kirkamide 1 and its derivatives 8, 11, and 13 were
evaluated as potential inhibitors of various N-acetyl-D-
glucosaminidases due to their structural similarity to the valien-
amine class of compounds and oseltamivir (4) [14,17,18]. We used a
panel of enzymes (HexB, EcNagZ, NAGLU, Jack bean b-hexosamin-
idase, chitinase from Streptomyces griseus (S. griseus), human chi-
totriosidase and BbLNBase) that are known N-acetyl-D-
glucosaminidases (Table 1). Interestingly kirkamide (1) was found
to be weakly active against human NAGLU (IC50 ¼ 240 mM) and was
modestly active against the other N-acetylglucosaminidases that
process single GlcNAc residues. From all the hybrid derivatives, 13
possessing an amine functional group at the C(1) position exhibits
the highest inhibition for HexB, EcNagZ, Jack bean b-hexosamini-
dase and BbLNBase. In comparison, kirkamide (1) displays generally
better activity than the oxidized derivatives 8 and 11, and surpris-
ingly, replacement of the OH group by the basic amine (/ 13)
resulted in better activity against three of the enzymes tested
(HexB, EcNagZ, NAGLU).
In addition, we assessed kirkamide (1) and the synthesized
derivatives against a neuraminidase from Clostridium perfringens
(C. perfringens) due to the structural similarity of 1with oseltamivir
(4). Interestingly compounds 11 and 13 possess potency towards
the enzyme even though they lack the 3-pentyl sidechain of 4,
which is generally required for good activity against bacterial and
viral neuraminidases [14,19]. Interestingly, the des-3-pentyl de-
rivative of oseltamivir (4) also displayed only micromolar activity
and the introduction of the 3-pentyl chain boosted activity by three
orders of magnitude [14].
Another possible mode of action, and potentially more inter-
esting, is that kirkamide (1) acts as a N-acetylglucosamine surro-
gate and is incorporated into the UDP-GlcNAc (14) salvage pathway
found within eukaryotes [20]. Kirkamide (1) would be metabolized
into UDP-kirkamide (15) (Fig. 2) and potentially act as an inhibitor
of O-GlcNAc transferases, critical enzymes in chitin biosynthesis
[21], a common polysaccharide found in arthropods and insects
[22]. Indeed, this type of incorporation of unnatural GlcNAc-based
compounds has literature precedent [23e25].
We decided to use a model system taking advantage of the O-
GlcNAc modification which is a post-translational modification
found in eukaryotes with the enzyme facilitating this modification,
O-GlcNAc transferase (OGT) using UDP-GlcNAc (14) as its substrate.
Utilizing a per-acetylated version of kirkamide 16, prepared by
treatment of kirkamide (1) with excess acetic anhydride, we treated
Scheme 1. Synthesis of the carboxylic acid derivative 8. a) Pd(OAc)2, PPh3, CO, NEt3,
68%; b) TBAF, 74%; c) BCl3, Me5C6H, CH2Cl2; d) KOH, 53% over 2 steps.
Scheme 2. Synthesis of the epimer at position 1. a) MsCl, DMAP, NEt3,71%; b) KNO2, 18-
crown-6, 57%; c) BCl3, Me5C6H, CH2Cl2; d) KOH, 52% over 2 steps.
Scheme 3. Synthesis of the amine derivative 13. a) NaN3; b) PPh3, 62% over 2 steps; c)
BCl3, Me5C6H, CH2Cl2; d) KOH, 94% over 2 steps.
Table 1
Inhibitory activity (IC50, mM) of kirkamide (1) and derivatives.
1 8 11 13
Human Hexosaminidase B (HexB) 689 >1000 >1000 280
NagZ from E. coli (EcNagZ) 624 912 >1000 347
Human NAGLU 240 595 >1000 881
Jack bean b-hexosaminidase 720 >1000 776 130
Chitinase from S. griseus >1000 >1000 >1000 >1000
Human Chitotriosidase >1000 >1000 >1000 >1000
BbLNBase 830 >1000 >1000 764
Neuraminidase from C. perfringens >500 >500 96 75
Fig. 2. Comparison between the structure of UDP-GlcNAc (14) and UDP-kirkamide
(15).
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the model cell line COS-7 using various concentrations of 16. A
similar strategy has been applied for other systems and showed an
increase in the uptake of carbohydrate-based compounds into cells
[26]. Unfortunately, we found that there was no clear decrease in O-
GlcNAc modified proteins even at high concentrations of 16 (Fig. 3)
and concentrations of 16 above 1.5 mMwere toxic. This result does
not rule out that kirkamide (1) is converted to UDP-kirkamide (15)
to act as a protective compound against organisms affecting Psy-
chotria-Burkholderia leaf nodule symbiosis but further studies are
required to evaluate this hypothesis.
Finally, we have investigated the possibility that the oxidized
kirkamide derivative 8 is present in planta, for example as a by-
product by oxidation of the allylic methylene group of 1. In addi-
tion, we wanted to test if plant extracts are able to mediate the
oxidation of 1 to 8. However, under several conditions evaluated, no
oxidation products such as 8 could be detected. While this does not
rule out that no oxidation takes place in planta, these observations
together with the decreased biological activity against some of the
enzymes tested in this study, render the carboxylate 8 less likely to
be an active material in the Burkholderia/Psychotria symbiosis.
3. Conclusions
In conclusion, the mechanism of action of kirkamide (1) was
investigated by testing its activity against enzymes involved in the
metabolism of structurally related compounds. Surprisingly, kir-
kamide (1) did not exhibit a strong inhibition against these po-
tential biological targets. Furthermore, hybrid oseltamivir-
kirkamide derivatives were synthesized using a divergent
approach and the compounds were evaluated. Interestingly some
of the derivatives showed a low micromolar activity against neur-
aminidases which could result in the development of kirkamide-
based compounds towards this important class of enzyme. Over-
all, based on this and previously published data and the strong
phenotype activity of kirkamide (1) on insects and arthropods, we
hypothesize that the natural product target(s) is/are related to
other metabolic pathways that await discovery.
4. Experimental section
4.1. General information, materials and equipment
All chemicals were purchased from Acros, Fluka or Sigma-
Aldrich and were used without further purification (except for
Et3N, which was freshly distilled before use). All reactions were
carried out in heat gun-dried glassware (unless aqueous reagents
were used) and reactions involving air sensitive compounds were
performed under an argon or nitrogen atmosphere. Solvents
applied for chemical transformations were either puriss quality or
HPLC grade solvents, which had been dried by filtration through
activated aluminum oxide under nitrogen (H2O content <10 ppm,
Karl-Fischer titration). For work-up and purification solvents were
distilled from technical grade. All synthetic transformations were
monitored either by thin layer chromatography (TLC) or 1H NMR
spectroscopy. Yields refer to purified, dried and spectroscopically
pure compounds. TLC was performed on Merck silica gel 60 F254
plates (0.25 mm thickness) pre-coated with a fluorescent indicator.
Concentration under reduced pressure was performed by rotary
evaporation at 40 C. Flash chromatography was performed using
silica gel 60 (230e400 mesh) from Sigma-Aldrich with a forced
flow eluent at 0.1e0.3 bar pressure. Preparative HPLC was carried
out on a Shimadzu HPLC system and a fraction collector. All 1H and
13C NMR spectra were recorded using a Bruker Avance 400 MHz,
500 MHz, 600 MHz (1H) & 101 MHz or 126 MHz (13C) spectrometer
at RT (unless otherwise stated). Chemical shifts (d-values) are re-
ported in ppm, spectra were calibrated relative to the residual
proton chemical shifts (CHCl3, d ¼ 7.26; D2O, d ¼ 4.79;
DMSO‑d6 ¼ d ¼ 2.50) and the residual carbon chemical shifts
(CDCl3, d¼ 77.16, DMSO‑d6, d¼ 39.52) of the solvents, multiplicity is
reported as follows: s¼ singlet, d¼ doublet, t¼ triplet, q¼ quartet,
m ¼ multiplet or unresolved and coupling constant J in Hz. IR
spectra were recorded on a PerkinElmer SpectrumTwo ATR-FTIR.
The absorptions are reported in cm1. All mass spectra (HRMS-
ESI) were recorded by the Mass Spectrometric Service of the Uni-
versity of Zürich on a QExactive instrument (Thermo Fisher Sci-
entific, Bremen, Germany) equipped with a heated electrospray
(ESI) ionization source and connected to a Dionex Ultimate 3000
UHPLC system. Melting points (M.p.) were determined using a
Büchi B-545 apparatus in open capillaries and are uncorrected.
Optical rotations ½aTD were measured at the sodium D line using a
1 mL cell with a 1 dm or 0.1 dm path length on a Jasco P-2000
digital polarimeter and the concentration c is given in g/100 mL
CHCl3.
4.2. Biological assay
4.2.1. Kinetic analysis of kirkamide (1)
Assays against the enzymes were carried out in triplicate at
37 C for 30 min using a stopped assay procedure in which the
enzymatic reactions were quenched by the addition of a 4-fold
excess of quenching buffer (200 mM glycine, pH 10.75). Assays
against HexB were conducted in buffer (50 mM sodium citrate,
100 mM NaCl, pH 4.25), jack bean b-hexosaminidase (50 mM so-
dium citrate, 100 mM NaCl, 0.1% BSA w/v, pH 5.0) and EcNagZ
(50mMHepes, 500mMNaCl, pH 7.1) using 4-nitrophenylN-acetyl-
b-D-glucosaminide as substrate. Assays against human chito-
triosidase were conducted in buffer (100 mM sodium citrate,
200 mM sodium phosphate, pH 5.2), Chitinase from S. griseus
(50 mM sodium citrate, 50 mM sodium phosphate buffer, pH 5.0)
using 4-methylumbelliferyl b-D-N,N0,N00-triacetylchitotriose as
substrate. Assays against Bifidobacterium bifidum lacto-N-biosidase
(BbLNBase) were conducted in buffer (50 mM sodium citrate,
50 mM sodium phosphate, pH 4.5) using 4-methylumbelliferyl 3-
O-b-D-galactopyranosyl-N-acetyl-b-D-glucosaminide as substrate.
For NAGLU, assays were performed in sodium acetate buffer
(100 mM, pH 4.3), containing bovine serum albumin (0.5 mg ml1)
using 4-nitrophenyl N-acetyl-a-D-glucosaminide as substrate.
Fig. 3. Incubation of COS-7 cells with 16 causes no clear decrease in cellular levels of
O-GlcNAc-modified proteins. Western blot analysis of proteins from COS-7 cells
cultured for 24 h in the presence or absence of 16. A) Western blot analysis of cellular
O-GlcNAc levels using mouse anti-O-GlcNAc followed by goat anti-mouse HRP con-
jugate. B) Western blot of samples loaded in treated with mouse anti-b-actin followed
by a rabbit anti-mouse HRP conjugate reveals equivalent b-actin levels in each sample.
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Assays against the neuraminidase from C. perfringens were con-
ducted in buffer (50 mM sodium citrate, 50 mM sodium phosphate,
pH 5.0) using 2’-(4-methylumbelliferyl)-a-D-N-acetylneuraminic
acid as substrate. Output of activity after enzymatic reactions were
quenched was recorded using a Spectramax spectrometer (Mo-
lecular Devices) at 400 nm for those using 4-nitrophenolate as an
output and a Varian CARY Eclipse Fluorescence Spectrophotometer
96-well plate system using excitation and emission wavelengths of
368 and 450 nm respectively, with 5 mm slit openings for those
using 4-methylumbelliferonate as an output. Assays contained
substrate at the previously determined Km value of the substrate for
the enzyme, and the enzyme was at a concentration of 20 nM.
4.2.2. Cell culture and inhibition
COS-7 cells (Sigma Aldrich ECACC) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing high glucose and no
glutamine (Gibco) supplemented with 5% fetal bovine serum
(Bovogen) and 2 mM Glutamax (Gibco). Cells were maintained in a
humidified 37 C incubator with a 5% CO2 atmosphere. Aliquots of
inhibitor (stock in 95% ethanol) were delivered onto 100 mm tissue
culture plates, and the ethanol was evaporated before cells were
seeded onto the plate. The cells were incubated at 37 C for 24 h at
which time they reached ~80% confluence. The cells were washed
twice with DPBS (Gibco), removed from the plates by trituration
and pelleted (800g, 10 min). Cells were gently washed again with
cold DPBS, (10 ml), and pelleted. The cells could be frozen at80 C
at this point. Control cultures without inhibitor were treated in the
same manner.
4.2.3. Western blot analyses
Frozen cells pellets were thawed on ice, and lysed using cell lysis
buffer (1 ml of 50 mM Tris, pH 8.0, containing 150 mM NaCl, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.5%
sodium deoxycholate) and by inversion rotation at 4 C for 20 min.
Cell debris were removed by centrifugation at 14,000 rpm in an
Eppendorf 5430R microcentrifuge for 20 min at 4 C. The cell ly-
sates were then either used immediately or aliquoted and stored
at 80 C until required. SDS-PAGE loading buffer was added to an
aliquot of each sample, and after heating at 95 C for 10 min, ali-
quots were loaded onto 10% Tris$HCl polyacrylamide gels. After
electrophoresis, the samples were electroblotted to nitrocellulose
membrane (0.45 mm, Bio-Rad). The membranes were blocked using
2% BSA (fraction V, Sigma) in PBST (PBS pH 7.4, 0.1% [v/v] Tween-20)
and then incubatedwith blocking buffer containing the appropriate
primary antibody, washed with PBST and then incubated with a
horseradish peroxidise (HRP) conjugated secondary antibody. The
membranes were washed again and detection of secondary HRP
conjugate was done using a SuperSignal West Pico chemilumi-
nescent detection kit (Pierce) and Chemidoc MP Imaging system
(Biorad) (software Image Lab 5.2). For detection of O-GlcNAc
modified proteins, mouse anti-O-GlcNAc IgM (clone CTD 110.6,
BioLegend) was used as the primary antibody at a dilution of
1:2500, and goat anti-mouse-IgM-HRP conjugate (Santa Cruz
Biotechnology) was used as the secondary antibody at a dilution of
1:2500. For detection of b-actin levels, mouse monoclonal anti-b-
actin IgG (clone AC-40, Sigma) was used as the primary antibody at
a dilution of 1:4000, and rabbit anti-mouse-IgG-HRP conjugate





The enol triflate 5 (1052 mg, 1.67 mmol), Pd(OAc)2 (75 mg,
0.33 mmol), PPh3 (177 mg, 0.67 mmol), Et3N (341 mg, 3.34 mmol),
DMF (20 mL), and EtOH (10 mL) were added to a Schlenk tube, and
the mixture was degassed by bubbling nitrogen gas for 10 min and
bubbling CO gas for another 10 min. The reaction was stirred under
CO atmosphere (1 atm) at 65 C for 2 h. The reaction was cooled to
RT, quenched with H2O (50 mL), extracted with EtOAc (125 mL x 2),
the combined organic layers were washed with brine (50 mL x 2),
dried over MgSO4 and concentrated under reduced pressure to
afford a brownish oil. The residue was purified by column chro-
matography (SiO2), eluted with pentane/Et2O 2/1 to 1/1 to afford
the ethyl ester 6 (627 mg, 1.13 mmol, 68% yield) as a colourless oil.
TLC (pentane/Et2O ¼ 1/1), Rf ¼ 0.4.
1H NMR (400 MHz, CDCl3):
d ¼ 7.43e7.23 (m, 10H), 6.75 (dt, J ¼ 2.4, 0.9 Hz, 1H), 6.00 (d,
J ¼ 8.8 Hz, 1H), 4.68e4.54 (m, 5H), 4.51 (d, J ¼ 10.5 Hz, 1H),
4.32e4.21 (m, 3H), 4.04 (dd, J ¼ 4.7, 2.7 Hz, 1H), 1.77 (s, 3H), 1.32 (t,
J ¼ 7.1 Hz, 3H), 0.88 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H); 13C NMR
(100 MHz, CDCl3): d ¼ 169.95, 165.64, 141.52, 137.64, 129.91, 129.55,
128.57, 128.40, 128.21, 128.04, 127.98, 127.86, 123.48, 77.20, 74.46,
73.82, 72.69, 72.43, 65.57, 60.93, 48.13, 25.74, 23.29, 18.11,
14.25, 4.96, 5.06; IR (ATR): n ¼ 3426, 2954, 2857, 2830, 1720,
1682, 1521, 1381, 1249, 1065, 838, 698 cm1; ESI-MS (ESþ) found




To a solution of the TBS protected ester 6 (626 mg, 1.13 mmol) in
THF (25mL, dry), a TBAF solution (1.36 mL,1.0 M in THF, 1.36mmol)
was added at 0 C. The solution was warmed to RT and stirred for
2 h. The solvent was evaporated under reduced pressure and the
residuewas purified by column chromatography, (SiO2) elutedwith
EtOAc to afford the alcohol 7 (371 mg, 0.84 mmol, 74% yield) as a
white solid. TLC (100% EtOAc), Rf ¼ 0.38.
1HNMR (400MHz, CDCl3):
d 7.39e7.26 (m, 10H), 7.07 (d, J ¼ 7.9 Hz, 1H), 6.94 (t, J ¼ 1.7 Hz, 1H),
4.78e4.72 (m, 2H), 4.72e4.64 (m, 1H), 4.62e4.50 (m, 3H),
4.39e4.33 (m, 1H), 4.32e4.19 (m, 2H), 3.84 (dd, J ¼ 4.0, 2.2 Hz, 1H),
1.81 (s, 3H), 1.32 (t, J ¼ 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d ¼ 172.56, 165.59, 141.70, 137.26, 137.09, 128.61, 128.59, 128.31,
128.23, 128.19, 128.15, 127.69, 77.2, 74.16, 74.10, 72.09, 71.95, 67.23,
60.97, 48.74, 23.10, 14.21; IR (ATR): n ¼ 3379, 2901, 1717, 1657, 1543,
1248, 1073, 749, 699 cm1; ESI-MS (ESþ) found 440.2065 (Mþ Hþ),
calc 440.2068 (M þ Hþ); ½aRTD ¼ þ32.5 (c ¼ 0.5, CHCl3).
4.3.3. (3S,4S,5R,6R)-4-acetamido-3,5,6-trihydroxycyclohex-1-ene-
1-carboxylic acid (8)
General Procedure 1: Step 1: To a solution of the ester 7 (15 mg,
34 mmol) and pentamethylbenzene (10 mg, 68 mmol) in dry CH2Cl2
(0.5 mL), BCl3 (273 mL, 273 mmol, 1.0 M in CH2Cl2) was added
at 78 C and the reaction was stirred at 78 C for 1 h. MeOH
(1 mL) was added to quench the reaction, then the solvent was
removed under reduced pressure. The residue was dissolved in H2O
(2.0 mL), washed with pentane (2.0 mL x 3), the aq. layer was
concentrated under reduced pressure and the residue was used in
the next step without further purification. Step 2: To a solution of
the triol intermediate (6.7 mg) in H2O (0.5 mL), a KOH solution
(97 mL, 1.0 M, 97 mmol) was added at RT. The reactionwas stirred for
1 h, neutralized to pH¼ 5 using Amberlyst 15 resin, filtered through
a short pad of celite and the compound was washed with EtOH. The
filtrate was concentrated under reduced pressure and purified by a
preparative HPLC system equipped with a RP-HPLC column (Syn-
ergi hydro, Phenomenex) to obtain the carboxylic acid 8 (4.1 mg,
18 mmol, 53% yield over 2 steps) as a white solid. M.p.:
205.5e206.6 C. 1H NMR (500 MHz, D2O): d 6.39 (d, J ¼ 5.2 Hz, 1H),
4.39 (d, J ¼ 7.7 Hz, 1H), 4.33 (t, J ¼ 4.7 Hz, 1H), 3.97 (dd, J ¼ 11.3,
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4.1 Hz, 1H), 3.78 (dd, J ¼ 11.3, 7.6 Hz, 1H), 2.08 (s, 3H); 13C NMR
(125 MHz, D2O þ CD3OD): d ¼ 175.83, 175.57, 141.04, 130.82, 73.72,
71.32, 66.08, 53.86, 23.45; IR (ATR): n ¼ 3299, 1650, 1572,
1376 cm1; ESI-MS (ESe) found 230.0668 (MeHþ), calc 230.0670
(MeHþ); ½aRTD ¼ þ58.2 (c ¼ 2.16, MeOH).
4.3.4. Ethyl (3S,4R,5R,6R)-4-acetamido-5,6-bis(benzyloxy)-3-
((methylsulfonyl)oxy)cyclohex-1-ene-1-carboxylate (9)
To a cold (0 C) solution of the alcohol 7 (288 mg, 0.66 mmol) in
CH2Cl2 (10 mL), MsCl (150 mg, 1.31 mmol), DMAP (16 mg,
0.13 mmol) and NEt3 (370 mL, 2.62 mmol) were slowly added. The
reactionwas stirred at 0 C for 1 h and at RT for 1 h. The solvent was
removed under reduced pressure and the residue was directly
purified by column chromatography (SiO2), eluted with Et2O to
afford the mesylate 9 (244 mg, 0.47 mmol, 71% yield). TLC (100%
Et2O), Rf ¼ 0.35.
1H NMR (400 MHz, CDCl3): 7.42e7.22 (m, 10H),
6.90e6.84 (m, 1H), 6.61 (d, J ¼ 9.4 Hz, 1H), 5.63e5.54 (m, 1H),
4.91e4.80 (m,1H), 4.71 (dd, J¼ 10.7, 0.7 Hz, 1H), 4.62e4.53 (m, 2H),
4.51 (d, J ¼ 10.7 Hz, 1H), 4.39e4.33 (m, 1H), 4.34e4.21 (m, 2H), 3.85
(dd, J ¼ 4.2, 2.5 Hz, 1H), 3.08 (s, 3H), 1.79 (s, 3H), 1.34 (t, J ¼ 7.1 Hz,
3H); 13C NMR (100 MHz, CDCl3): d ¼ 170.00, 164.70, 136.99, 136.85,
136.41, 131.69, 128.67, 128.58, 128.36, 128.29, 127.89, 77.20, 74.28,
74.23, 74.15, 72.40, 71.60, 61.35, 46.05, 38.71, 23.22, 14.17; IR (ATR):
n ¼ 3393, 2935, 1719, 1667, 1524, 1360, 1250, 1174, 961, 884,
741 cm1; ESI-MS (ESþ) found 518.1842 (M þ Hþ), calc 518.1843
(M þ Hþ); ¼ ½aRTD þ32.26 (c ¼ 1.0, CHCl3).
4.3.5. Ethyl (3R,4S,5R,6R)-4-acetamido-5,6-bis(benzyloxy)-3-
hydroxycyclohex-1-ene-1-carboxylate (10)
To a solution of the protected mesylate 9 (36 mg, 70 mmol), 18-
crown-6-ether (1.8 mg, 7 mmol) in DMF (2.0 mL) and KNO2 (30 mg,
348 mmol) were added at RT. The reactionwas stirred at RT for 16 h,
then diluted with EtOAc (15 mL), and washed with brine (5 mL x 2),
dried over MgSO4 and concentrated under reduced pressure. The
residuewas purified by column chromatography (SiO2), elutedwith
EtOAc to afford the alcohol 10 (18mg, 40 mmol, 57% yield) as awhite
solid. TLC (100% EtOAc), Rf ¼ 0.31.
1H NMR (400 MHz, CDCl3):
d 7.42e7.22 (m, 10H), 7.11e7.05 (m, 1H), 6.57 (d, J ¼ 7.7 Hz, 1H), 4.75
(d, J¼ 10.7 Hz,1H), 4.64e4.54 (m, 3H), 4.51e4.45 (m, 2H), 4.37e4.19
(m, 2H), 4.16e4.07 (m, 1H), 3.90e3.83 (m, 1H), 3.25 (d, J ¼ 10.2 Hz,
1H), 1.75 (s, 3H), 1.34 (t, J ¼ 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d ¼ 169.70, 166.11, 139.36, 137.29, 136.64, 128.93, 128.76, 128.61,
128.44, 128.30, 128.22, 128.04, 77.20, 74.24, 73.81, 72.60, 71.98,
67.14, 61.18, 49.90, 23.14, 14.21; IR (ATR): n¼ 3300, 2872,1717,1548,
1251, 1055, 738, 698 cm1; ESI-MS (ESþ) found 440.2067 (Mþ Hþ),
calc 440.2068 (M þ Hþ); ½aRTD ¼ e 84.38 (c ¼ 1.0, CHCl3).
4.3.6. (3R,4S,5R,6R)-4-acetamido-3,5,6-trihydroxycyclohex-1-ene-
1-carboxylic acid (11)
This compound was synthesized from the alcohol 10 following
general procedure 1 used for the compound 8. The obtained yield
was 52% over 2 steps starting from 10 mg of starting material.
Isolated as a white solid; m.p.: 128.1e128.8 C; 1H NMR (500 MHz,
D2O): d 6.69 (s, 1H), 4.56 (d, J ¼ 8.0 Hz, 0H), 4.40 (dt, J ¼ 9.5, 2.5 Hz,
1H), 3.91 (dd, J¼ 11.3, 9.3 Hz,1H), 3.65 (dd, J¼ 11.3, 7.7 Hz,1H), 2.08
(s, 2H); 13C NMR (125 MHz, D2O þ CD3OD): d ¼ 176.49, 171.46,
140.67, 134.36, 74.75, 72.72, 70.71, 57.79, 23.68; IR (ATR): n ¼ 3314,
1699, 1644, 1564, 1253 cm1; ESI-MS (ESþ) found 232.0813
(M þ Hþ), calc 232.0816 (M þ Hþ); ½aRTD ¼ þ70.6 (c ¼ 0.8, MeOH).
4.3.7. Ethyl (3R,4S,5R,6R)-4-acetamido-3-azido-5,6-bis(benzyloxy)
cyclohex-1-ene-1-carboxylate (17)
To a solution of the mesylate 9 (100 mg, 0.19 mmol) in acetone
(4.0 mL), a solution of NaN3 (50 mg (0.77 mmol) in water (1 mL))
was added at 0 C. The reactionwas stirred at 0 C for 4 h, quenched
with a sat. NaHCO3 soln. (2.0 mL), the compounds were extracted
with EtOAc (10 mL x 2). The organic layers were combined, washed
with brine (10 mL), dried over MgSO4 and concentrated under




To a solution of the azide 17 (12 mg) in THF (0.5 mL) with H2O
(30 mL), PPh3 (20.5mg 77 mmol) was added. The reactionwas stirred
under nitrogen at RT for 2 h and then mixture was purified by
column chromatography (SiO2), eluted with CH2Cl2/MeOH 20/1 to
10/1 to afford the amine 12 (7mg,16 mmol 62% yield over 2 steps) as
a yellowish oil. TLC (CH2Cl2/MeOH ¼ 10/1), Rf ¼ 0.30.
1H NMR
(400MHz, CDCl3): d 7.40e7.22 (m,10H), 7.12 (dd, J¼ 4.6, 1.2 Hz,1H),
6.87 (d, J ¼ 8.2 Hz, 1H), 4.73 (d, J ¼ 10.7 Hz, 1H), 4.64e4.51 (m, 3H),
4.48 (dd, J ¼ 2.3, 1.2 Hz, 1H), 4.46e4.40 (m, 1H), 4.34e4.22 (m, 2H),
3.86 (dd, J¼ 3.5, 2.3 Hz, 1H), 3.39 (d, J¼ 4.5 Hz, 1H), 1.74 (s, 3H), 1.71
(s, 2H), 1.34 (t, J ¼ 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d ¼ 169.31, 166.39, 142.57, 137.42, 137.20, 128.60, 128.27, 128.25,
128.10, 127.70, 127.21, 77.20, 73.94, 73.52, 71.97, 71.51, 60.99, 51.15,
50.98, 23.21, 14.24; IR (ATR): n ¼ 3380, 2903, 1715, 1659,1526, 1370,
1252, 1068,739, 699 cm1; ESI-MS (ESþ) found 439.2229 (M þ Hþ),
calc 439.2228 (M þ Hþ); ½aRTD ¼ 79.49 (c ¼ 1.25, CHCl3).
4.3.9. (3R,4S,5R,6R)-4-acetamido-3-amino-5,6-dihydroxycyclohex-
1-ene-1-carboxylic acid (13)
This compound was synthesized from the amine 12 following
general procedure 1 used for the compound 8. The obtained yield
was 94% over 2 steps starting from 10 mg of starting material.
Isolated as a white solid, m.p.: 213.5e214.3 C; 1H NMR (500 MHz,
D2O): d 6.21 (s, 1H), 4.54 (d, J ¼ 8.3 Hz, 1H), 4.16e4.04 (m, 2H),
3.78e3.72 (m, 1H), 2.10 (s, 3H); 13C NMR (125 MHz, D2O þ CD3OD):
d ¼ 176.90, 174.40,142.89, 126.39, 73.96, 73.06, 54.05, 53.78, 23.63;
IR (ATR): n¼ 3262, 2982, 1563, 1374, 1054, 1033, 1016 cm1; ESI-MS
(ESþ) found 231.0976 (M þ Hþ), calc 231.0976 (M þ Hþ);
½aRTD ¼ 11.2 (c ¼ 0.8, H2O).
4.3.10. 1R,2R,3S,4S)-3-acetamido-6-(acetoxymethyl)cyclohex-5-
ene-1,2,4-triyl triacetate (16)
A sealed tubewas charged with kirkamide (20mg, 0.092mmol),
sodium acetate (90.7 mg, 1.11 mmol) and acetic anhydride (2 mL).
The reaction was stirred at 90

C for 2 h. After consumption of the
starting material, the reaction was quenched with ice and sat.
NaHCO3 soln. (3 mL). The aqueous phase was extracted with ethyl
acetate (15 mL x 2) and the combined organic phases were washed
with brine (5 mL x 2), dried over Na2SO4 and evaporated under
reduced pressure. The product 16 was obtained as a pale yellow oil
(32 mg, 0.086 mmol 93% yield). TLC (CH2Cl2/MeOH ¼ 10/1),
Rf ¼ 0.5;
1H NMR (400 MHz, CDCl3): d 6.10 (dt, J ¼ 5.5, 1.5 Hz, 1H),
5.85e5.74 (m, 2H), 5.33e5.25 (m, 2H), 4.68 (dd, J¼ 13.3, 1.2 Hz, 1H),
4.53 (ddd, J¼ 11.5, 9.4, 3.9 Hz,1H), 4.36 (dd, J¼ 13.4,1.0 Hz,1H), 2.11
(s, 3H), 2.06e2.03 (m, 9H), 1.94 (s, 3H); 13C NMR (101 MHz, CDCl3):
d 171.66 (s), 170.28 (s), 169.82 (s), 169.73 (s), 169.65 (s), 137.15 (s),
124.51 (s), 70.96 (s), 69.99 (s), 67.94 (s), 62.53 (s), 48.92 (s), 23.09
(s), 20.91 (s), 20.75 (s), 20.64 (s), 20.57 (s); IR (ATR): n¼ 3328, 2954,
1745, 1666, 1371, 1225, 1046 cm1; ESI-MS (ESþ) found 386.1439
(M þ Hþ), calc 386.1451 (M þ Hþ); ½aRTD ¼ þ24.7 (c ¼ 0.15, CHCl3).
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